| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/30/2002 | WO2000051564A8 Echinocandin pharmaceutical formulations containing micelle-forming surfactants |
| 05/30/2002 | WO2000013684A3 Pharmaceutical composition and method for treatment of inflammation |
| 05/30/2002 | US20020065419 Cyclobutenedione compounds |
| 05/30/2002 | US20020065418 Viral polymerase inhibitors |
| 05/30/2002 | US20020065416 Anti-inflammatory agents |
| 05/30/2002 | US20020065395 Polypeptide for use as diagnostic tool in screening bactericides |
| 05/30/2002 | US20020065327 Pharmaceutically active compounds and methods of use thereof |
| 05/30/2002 | US20020065326 Patient oxygenation using stabilized fluorocarbon emulsions |
| 05/30/2002 | US20020065325 Use of CLC3 chloride channel blockers to modulate vascular tone |
| 05/30/2002 | US20020065324 Methods of inducing ovulation |
| 05/30/2002 | US20020065323 Agmatine and agmatine analogs in the treatment of epilepsy, seizure, and electroconvulsive disorders |
| 05/30/2002 | US20020065322 Naphthylsalicylanilides as antimicrobial and antiinflammatory agents |
| 05/30/2002 | US20020065321 Nasal administration of agents for the treatment of gastroparesis |
| 05/30/2002 | US20020065320 For treatment of thromboses not induced by hyperhomocystenemia or homocystinuria, of blood disorders, such as blood coagulation, thrombi formation |
| 05/30/2002 | US20020065319 For use in therapy of schizophrenia and/or tardive dyskinesia |
| 05/30/2002 | US20020065318 Postsurgical treatment with dichloroacetate |
| 05/30/2002 | US20020065316 Citrullimycines, a process for their production and their use as pharmaceuticals |
| 05/30/2002 | US20020065315 For therapy and prophylaxis of asthma, cystic fibrosis, chronic obstructive pulmonary disease and rhinorrhea, convulsions, vascular spasms, coronary artery spasms, renal disorders, polycystic kidney disease, bladder spasms, etc. |
| 05/30/2002 | US20020065314 Compositions and method for stimulating hair growth |
| 05/30/2002 | US20020065311 Comprehensive pharmacologic therapy for treatment of obesity |
| 05/30/2002 | US20020065310 Method for treatment of tumors using nordihydroguaiaretic acid derivatives |
| 05/30/2002 | US20020065309 For therapy of sex-hormone related conditions, as contraceptives |
| 05/30/2002 | US20020065308 EP4 receptor selective agonists in the treatment of osteoporosis |
| 05/30/2002 | US20020065306 Methods for prevention of ulcers and improving physiological performance |
| 05/30/2002 | US20020065305 As antitumor agent |
| 05/30/2002 | US20020065304 As antitumor agent |
| 05/30/2002 | US20020065302 Cyclic AMP-specific phosphodiesterase inhibitors |
| 05/30/2002 | US20020065301 Paroxetine compositions and processes for making the same |
| 05/30/2002 | US20020065299 Administering for therapy of mitochondria medited disease |
| 05/30/2002 | US20020065298 Mitochondria protecting agents for treating mitochondria associated diseases |
| 05/30/2002 | US20020065297 For therapy of alopecia |
| 05/30/2002 | US20020065296 Administering heteroarylurea compound for therapy of cytokine mediated diseases and proteolytic enzyme mediated diseases |
| 05/30/2002 | US20020065294 Novel therapeutic use of 1,6-dimethyl-8b-hydroxymethyl-10a-methoxyergoline |
| 05/30/2002 | US20020065293 Administering2-(((3-hydroxypropyl)amino)-6-benzylamino)-9 -isopropylpurine or its salt for therapy of leukemia |
| 05/30/2002 | US20020065292 Pyrazole compounds, pharmaceutical compositions, and methods for modulating or inhibiting ERAB or HADH2 activity |
| 05/30/2002 | US20020065290 Used as corticotropin-releasing factor (CRF) antagonists, in therapy and diagnosis of stress related disorders such as post traumatic stress disorder (PTSD) as well as depression, headache and anxiety |
| 05/30/2002 | US20020065289 Amino pyrazole derivatives useful for the treatment of obesity and other disorders |
| 05/30/2002 | US20020065287 Methods for the preparation of polymorphs of doxazosin mesylate |
| 05/30/2002 | US20020065286 Treating chronic venous ulcers, arterial ulcers, chronic decubitus, acute wounds with a cGMP PDE5 inhibitor, such as Sildenafil; improved blood supply to the wound region; also in combination with a matrix metalloprotease inhibitor and/or a urokinase type plasminogen activator inhibitor |
| 05/30/2002 | US20020065285 Aromatic heterocyclic compounds as antiinflammatory agents |
| 05/30/2002 | US20020065284 Dipeptide derivatives |
| 05/30/2002 | US20020065282 Tetralone derivatives |
| 05/30/2002 | US20020065281 Compositions containing a benzamide disulfide derivative for treating allergic diseases |
| 05/30/2002 | US20020065280 Oxazolidinones to treat eye infections |
| 05/30/2002 | US20020065279 Arylsulfonic acid salts of pyrimidine-based antiviral |
| 05/30/2002 | US20020065278 Non-imidazole aryloxyalkylamines |
| 05/30/2002 | US20020065277 Administering to an obese patient or a patient at risk of becoming obese therapeutically effective amount of compound that attenuates binding of agouti-related protein to melanocortin receptors |
| 05/30/2002 | US20020065276 N-triazolymethyl-piperazine compounds with neurokinin-receptor antagonist activity |
| 05/30/2002 | US20020065275 To increase insulin secretion, which makes them useful for treating type II diabetes |
| 05/30/2002 | US20020065273 Hormone therapy methods and hormone products for abating coronary artery blockage |
| 05/30/2002 | US20020065272 Olanzapine-N-oxide compositions and methods |
| 05/30/2002 | US20020065269 3-Sulfonylamino-c5 to c8-methyleneimino-2-carboxylic acid compound is effective for prophylaxis and treatment of inflammation, tissue degradation, cancer, fibrosis and related diseases |
| 05/30/2002 | US20020065266 Bicyclic or tricyclic ketones, oximes, amine oxides or amines are used as calcium or potassium channel modulators |
| 05/30/2002 | US20020065264 Heterocylic leaving group containing -o-Het, or -s-Het, wherein Heterocyclic rings selected from pyridine, pyrole, furan, pyrimidine or proline derivatives |
| 05/30/2002 | US20020065263 Formulation |
| 05/30/2002 | US20020065260 Pharmaceutical preparations for treating side effects during and/or after GnRHa therapy |
| 05/30/2002 | US20020065259 Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| 05/30/2002 | US20020065257 17beta-amino and hydroxylamino-11beta-arylsteroids and their derivatives having agonist or antagonist hormonal properties |
| 05/30/2002 | US20020065256 Antiinflammatory and antiallergic glucocorticosteroid, sterile glucocorticosteroids |
| 05/30/2002 | US20020065254 Phenolic esters of ibuprofen with salicylic acid or its nontoxic salts used as antitumor agent |
| 05/30/2002 | US20020065253 Administering to a mammal a cyclic compound (acyclic, carbocyclic or heterocyclic) substituted by at least three vicinal phosphorus containing radicals for treating angiogenesis in tumor conditions |
| 05/30/2002 | US20020065252 Orally administering to a mammal a bisphosphonate selected from alendronate, ibandronate, risedronate or salts or esters as a unit dosage according to a continuous schedule interval |
| 05/30/2002 | US20020065248 Pyrrolopyrazinones useful as serine protease inhibitors |
| 05/30/2002 | US20020065247 Triarylmethane derivatives having inhibitory activity on an intermediate conductance Calcium ion activated potassium channel (IKCa) |
| 05/30/2002 | US20020065246 Useful agents in the treatment of inflammatory diseases such as asthma, arthritis, inflammatory bowel disease and neurodegenerative diseases |
| 05/30/2002 | US20020065241 A recombinant polynucleotide of first polynucleotides coding an antigenic peptide and are operatively linked to each other to enhance translation of the polynucleotides to the peptides and binding to MHC; cancer vaccine |
| 05/30/2002 | US20020065235 Ketolide antibiotics |
| 05/30/2002 | US20020065234 Administering a synergistic antineoplatic mixture of paclitaxel and discodermoliide; antitumor, -carcinogenic and -proliferative agents; particularly cancer of the bladder, breast, colon, kidney, lung, neck and ovary |
| 05/30/2002 | US20020065233 Oral administration of Sulodexide in unit dosages suitable for the treatment of diabetic nephropathies in both macro and micro albuminic patients, producing immediate and lasting improvement in albumin excretion rate |
| 05/30/2002 | US20020065232 Administration of ribose one to four times a days, beginning immediately on encountering high altitudes and continuing for at least five days; antiischemic, hypoxia and -emetic agents |
| 05/30/2002 | US20020065230 Bis(aminomethyl)carbonyl compounds as inhibitors of cysteine protease (cathepsin K) and serine proteases; bone or cartilage loss, e.g., osteoporosis, periodontitis; antiarthritic agents; rheumatic diseases; gingivitis |
| 05/30/2002 | US20020065227 Charged compounds comprising a nucleic acid binding moiety and uses therefor |
| 05/30/2002 | US20020065220 For use in diagnosis and therapy of disorders treating disorders related to these novel human immunoglobulin-like (Ig- like) proteins |
| 05/30/2002 | US20020065213 Increasing the duration of expression of a delivered gene in target cells by delivering a gene encoding a cellular retention activity and nuclear binding sequence to target cells before or during gene of interest delivery |
| 05/30/2002 | US20020064848 Novel histidinol dehydrogenase |
| 05/30/2002 | US20020064826 Cytokine receptor-like polynucleotides, polypeptides, and antibodies |
| 05/30/2002 | US20020064812 Plasmid for use in the treatment of blood disorders |
| 05/30/2002 | US20020064790 Generating nucleotide sequence binding ligand; obtain ligandthat binds to nucleotide sequence, monitor binding activity of particle and sequences, recover ligands that utilizes reduced energy to bind sequences compare to wild type |
| 05/30/2002 | US20020064785 Gene detection assay for improving the likelihood of an effective response to an ErbB antagonist cancer therapy |
| 05/30/2002 | US20020064571 Inhibits elastase; inhibits inflammations; used for the preparation of a vasoregulatory and or collagen activating medicament and to treat gingivitis. |
| 05/30/2002 | US20020064569 Use of valeriana for the treatment of Restless Leg Syndrome and related disorders |
| 05/30/2002 | US20020064568 Product and method for treating joint disorders in vertebrates |
| 05/30/2002 | US20020064563 Core particles which are coated with a taste mask coating to provide coated particles which can be sprinkled onto food to ease administration to patients who have difficulty swallowing tablets or capsules |
| 05/30/2002 | US20020064562 Granulates compacted together into a tablet form together with an extra-granular lubricant; especially amoxycillin plus clavulanic acid, and crosslinked polyvinylpyrrolidone or sodium starch glycolate intra-granular disintegrant |
| 05/30/2002 | US20020064560 Hydrophobic and/or hydrophilic active agents and a polymeric emulsifier. |
| 05/30/2002 | US20020064556 Core containing the antihyperglycemic drug, a semipermeable membrane coating the core and at least one passageway in the membrane. |
| 05/30/2002 | US20020064553 Large liposome composition not increasing ldl levels and method of treating atherosclerosis related thereto |
| 05/30/2002 | US20020064552 Diseases and conditions responsive to selegiline include those produced by neuronal degeneration or neuronal trauma and those due to immune system dysfunction. |
| 05/30/2002 | US20020064540 Composition, particularly cosmetic, combining DHEA and/or a precursor or derivative thereof, and at least an agent for increasing glycosaminoglycan synthesis |
| 05/30/2002 | US20020064539 Cosmetic or dermatological composition contacting at least one natural or recombinant spider silk or an analog |
| 05/30/2002 | US20020064538 Using a compound that inhibits or induces expression of tropoelastin mRNA or protein in keratinocytes; prevents photoaging |
| 05/30/2002 | US20020064524 Formulation for topical non-invasive application in vivo |
| 05/30/2002 | US20020064522 Activated hemicellulose as active ingredient; use as anticancer agents |
| 05/30/2002 | US20020064515 Administering synergistic mixtures of immunostimulatory CpG oligonucleotides with unmethylated cytosine and guanine in given sequence, and immunopotentiating cytokines; treating tumors; contraceptive |
| 05/30/2002 | US20020064513 For therapy of eye infections such as conjunctivitis, blepharitis, keratitis sicca etc and to provide intraocular treatment through the cornea for diseases such as glaucoma or uveitis |
| 05/30/2002 | US20020064512 May be used for medical indications, such as an implantable or injectable endoprostheses for mammoplastic reconstruction, implantable or injectable endoprostheses for treating (reflux) oesophagitis, and for body contouring of various body parts |
| 05/30/2002 | US20020064511 Water-soluble polymers for the reduction of dietary phosphate or oxalate absorption |
| 05/30/2002 | US20020064505 Oral anti-odor compositions |
| 05/30/2002 | US20020064503 Administering dose of mixture of lipid crystals comprising surfactant and spreading agnet as aerosol through an external airway of a mammal for enhancing mammalian eustachian tube lumen patency and pressure equalization performance |
| 05/30/2002 | US20020062835 Methods of modulating hair growth |